Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma

Feline mammary carcinomas are characterized by rapid progression and metastases. Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis, proliferation and metastasis. The present study aimed to investigate the effects of a single drug therapy of bevacizumab on a xenograft...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Veterinary Medical Science 2016, Vol.78(4), pp.685-689
Main Authors: MICHISHITA, Masaki, OHTSUKA, Aya, NAKAHIRA, Rei, TAJIMA, Tsuyoshi, NAKAGAWA, Takayuki, SASAKI, Nobuo, ARAI, Toshiro, TAKAHASHI, Kimimasa
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - therapeutic use
Animals
bevacizumab
Bevacizumab - therapeutic use
Cat Diseases - drug therapy
Cat Diseases - metabolism
Cats
Cell Line, Tumor
Cell Proliferation - drug effects
feline mammary carcinoma
Male
Mammary Neoplasms, Animal - drug therapy
Mammary Neoplasms, Animal - metabolism
Mice
Mice, Inbred NOD
Pharmacology
Receptors, Vascular Endothelial Growth Factor - metabolism
vascular endothelial growth factor (VEGF)
Vascular Endothelial Growth Factors - metabolism
xenograft
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Feline mammary carcinomas are characterized by rapid progression and metastases. Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis, proliferation and metastasis. The present study aimed to investigate the effects of a single drug therapy of bevacizumab on a xenograft model of feline mammary carcinoma expressing VEGF protein. Bevacizumab treatment suppressed tumor growth by inhibiting angiogenesis and enhancing apoptosis; however, it did not affect the tumor proliferation index. Thus, bevacizumab had anti-tumor effects on a xenograft model, and this may be useful for the treatment of feline mammary carcinoma.
ISSN:0916-7250
1347-7439
DOI:10.1292/jvms.15-0550